ClinicalTrials.gg
RecruitingNCT06347796CHESSUpdated May 22, 2026

Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study

An interventional study of Conventional Surgery and Middle Meningeal Artery Embolization (MMAE) in Chronic Subdural Hematoma, sponsored by The University of Texas Medical Branch, Galveston. Recruiting at 31 sites in United States. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by The University of Texas Medical Branch, Galveston · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
40 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Hematoma, Subdural, Chronic with a site in United States — 10 open to participants now, 10 under way, none of them phase 3. Hematoma, Subdural, Chronic · United States.

Planned enrollment
Largest of 15
520 · median 40
Started
2024
with 2 others
No phase
10 of 22
4 open now
Registered
13th of 22
by date

Among the 22 studies in Hematoma, Subdural, Chronic with a site in United States, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 with no phase, and was the 13th registered.

Hematoma, Subdural, Chronic

113 studies on the registry are indexed under Hematoma, Subdural, Chronic; 50 are open to participants now.

Browse Hematoma, Subdural, Chronic studies →

Open to participants now

10 of the 22 studies in Hematoma, Subdural, Chronic with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hematoma, Subdural, Chronic studies recruiting now, 26 (72%) set no upper age limit and 1 (3%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 40 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Hematoma, Subdural, Chronic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test in moderately symptomatic chronic subdural hematoma (CSDH) patients if middle meningeal artery embolization (MMAE) can be used as an alternative to conventional open surgery. The main questions it aims to answer are:

  • Compared to open conventional surgery, does MMAE reduce the need for rescue surgery or deaths?
  • What is the safety of MMAE and conventional open surgery in these patients?

Participants will be asked to:

  • Share their medical history and undergo physical examinations
  • Have blood drawn
  • Have CT scans of the head
  • Answer questionnaires
  • Undergo MMAE or conventional open surgery
  • Provide information about possible adverse events Researchers will compare participants in the MMAE group with those in the conventional open surgery group to see if there is a reduced need for rescue surgery or deaths and evaluate safety.
03

Conditions studied

  • Chronic Subdural Hematoma

Keywords

  • chronic subdural hematoma (CSDH)
  • middle meningeal artery embolization (MMAE)
04

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 40-90 years inclusively.
  2. Per CT of the head, (one of the following): Unilateral convexity CSDH measuring at least 10 mm in thickness OR Bilateral CSDH if only one side is considered for treatment (at least 10 mm in thickness) and the contralateral side is asymptomatic and \< 10 mm in thickness.
  3. CSDH at least 2/3 isodense or hypodense, verified on axial CT slice used to measure the thickness of the qualifying CSDH.
  4. Qualifying baseline head CT performed within the 7 days prior to randomization.
  5. Able to undergo assigned treatment within 72 hours after randomization.
  6. Patient or legally authorized representative agrees to be randomized, and provides written and Health Insurance Portability and Accountability Act (HIPAA) authorization.

Exclusion criteria

Exclusion Criteria:

  1. Secondary cause apart from trauma for the qualifying SDH, such as an underlying vascular abnormality or tumor.
  2. Tentorial or interhemispheric SDH.
  3. Secondary to CSDH, MRC of 0, 1, 2, or 3 in any muscle group contralateral to the side of the CSDH 4.
  4. Pre CSDH mRS of 5 or higher.
  5. Secondary to CSDH, patient is unable to complete TUG (i.e.,TUG > 120 seconds, unable to walk, or tries TUG but quits in ≤ 120 seconds). Note: This criterion does not apply if the patient does not complete TUG for reason other than CSDH.
  6. Secondary to CSDH, ASR of 0, 1, or 2.
  7. Emergent surgical evacuation such as open craniotomy, burr hole drainage, or Subdural Evacuating Port System (SEPS) is required for the patient.
  8. Unable to withhold all antiplatelet agents or OACs for the first 7 days after randomization.
  9. Indication that withdrawal of care will be implemented for the qualifying SDH.
  10. Prior surgical treatment for CSDH if the surgery is less than 30 days prior to randomization.
  11. On tranexamic acid.
  12. count of \<100,000 per microliter to transfusion.
  13. Coagulopathy that cannot be corrected to an of ≤1.5.
  14. Known to angiography.
  15. Known intolerance to occlusion procedures.
  16. Known vascular anatomy (small artery size) or blood flow (high vascular resistance peripheral to the feeding arteries) that precludes catheter placement or embolic agent (Embosphere Microspheres or CONTOUR particles) injection.
  17. Known presence of collateral vessel pathways potentially endangering normal territories or cranial nerves during embolization.
  18. Known large diameter arteriovenous shunt, i.e., where the blood does not pass through an arterial/capillary/venous transition but directly from an artery to a vein or presence of patent extra-to-intracranial anastomoses (where study embolization devices could pass directly into the internal carotid artery, vertebral artery, or intracranial vasculature) that cannot be addressed with coil embolization.
  19. Patient has a known active systemic infection or sepsis.
  20. Patient is pregnant, planning to become pregnant, or lactating.
  21. of less than 6 months due to comorbid terminal conditions.
  22. Concurrent participation in another research protocol for investigation of an experimental therapy.
  23. Known or suspected to not be able to comply with the study protocol.
  24. For unilateral CSDH, no measurable deficit secondary to the CSDH on the Timed Up and Go [TUG], Aphasia Severity Rating [ASR], or MRC. At baseline, a measurable deficit on the TUG is defined as: time ≥10 seconds. At baseline, a measurable deficit on the ASR is defined as: a score ≤4. At baseline, a measurable deficit on the MRC is defined as: a score \< 5 in any muscle group contralateral to the site of the CSDH.
  25. For bilateral CSDH, no measurable deficit secondary to the treatment-eligible CSDH on the ASR or MRC. At baseline, a measurable deficit on the ASR is defined as: a score ≤4. At baseline, a measurable deficit on the MRC is defined as: a score \< 5 in any muscle group contralateral to the treatment-eligibile CSDH side.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
520 participants (estimated)

Study arms

  • Experimental
    Middle Menningeal Artery Embolization (MMAE)

    Device: Middle Meningeal Artery Embolization (MMAE)

  • Active comparator
    Conventional Surgery (Craniotomy or Burr Holes)

    Procedure: Conventional Surgery

Interventions

  • ProcedureConventional Surgery

    Conventional surgery is surgical drainage through burr holes or craniotomy.

  • DeviceMiddle Meningeal Artery Embolization (MMAE)

    Particle embolization of the middle meningeal artery with micron variants of the Embosphere Microspheres or CONTOUR Embolization Particles device.

06

What researchers measure

Primary outcomes

  1. Need for Rescue Surgery or Death

    Participants who need rescue surgery or die.

    Time frame: Within 180-210 days of randomization

Secondary outcomes

  1. Safety of MMAE and Conventional Open Surgery

    The proportion of subjects with symptomatic ischemic stroke, serious/life threatening adverse events, worsening of neurological status (a decline of 1 point on the Markwalder scale) or development of new disabling neurological symptoms, seizures, and/or cranial neuropathy.

    Time frame: Within 180 days of randomization.

07

Study locations

28 of 31 sites recruiting
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
    Recruiting
    • Bernard Bendok, MD · Principal investigator
  • Baptist Medical Center Jacksonville
    Jacksonville, Florida 32207, United States
    Recruiting
    • Ricardo Hanel, MD · Principal investigator
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
    Recruiting
    • Robert Starke, MD · Principal investigator
  • University of South Florida
    Tampa, Florida 33617, United States
    Recruiting
    • Maxim Mokin, MD · Principal investigator
  • Emory University
    Atlanta, Georgia 30322, United States
    Recruiting
    • Jonathan Grossberg · Principal investigator
  • University of Kansas Medical Center
    Kansas City, Kansas 61660, United States
    Recruiting
    • Koji Ebersole, MD · Principal investigator
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
    • Christopher Stapleton, MD · Principal investigator
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • Nirav Patel, MD · Principal investigator
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Recruiting
    • Philip Taussky, MD · Principal investigator
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of Missouri Healthcare
    Columbia, Missouri 65212, United States
    Recruiting
    • Brooke Hoffman · Contact
    • Steven Carr · Principal investigator
  • Washington University, St. Louis
    St Louis, Missouri 63110, United States
    Recruiting
    • Joshua Osbun, MD · Principal investigator
  • Cooper University Hospital
    Camden, New Jersey 08103, United States
    Recruiting
    • Sean Behnke · Contact
    • Daniel Tonetti, MD · Principal investigator
  • JFK Neuroscience Institute, JFK University Medical Center
    Edison, New Jersey 08820, United States
    Recruiting
    • Brian Jankowitz, MD · Principal investigator
  • Rutgers, The State University of New Jersey
    Newark, New Jersey 07101, United States
    Recruiting
    • Amit Singla, MD · Principal investigator
  • Ichan School of Medicine at Mount Sinai
    New York, New York 10029, United States
    Recruiting
    • Christopher Kellner, MD · Principal investigator
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Montefiore Medical Center
    The Bronx, New York 10467, United States
    Recruiting
    • David Altschul, MD · Principal investigator
  • Westchester Medical Center
    Valhalla, New York 10595, United States
    Recruiting
    • Chirag Gandhi, MD · Principal investigator
  • Wake Forest University
    Winston-Salem, North Carolina 27157, United States
    Recruiting
    • Stacey Wolfe, MD · Principal investigator
  • Good Samaritan Hospital
    Cincinnati, Ohio 45220, United States
    Recruiting
    • Andrew Ringer, MD · Principal investigator
  • Mercy Health St. Vincent Medical Center
    Toledo, Ohio 43608, United States
    Not yet recruiting
    • Osama Zaidat, MD · Principal investigator
  • University of Pennyslvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Jan Burkhardt, MD · Principal investigator
  • Philadelphia Neurological Institute
    Upland, Pennsylvania 19013, United States
    Recruiting
    • Mandy Binning, MD · Principal investigator
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
    Recruiting
    • Babu Welch, MD · Principal investigator
  • University of Texas Medical Branch
    Galveston, Texas 77555, United States
    Recruiting
  • University of Texas Health Science Center-Houston
    Houston, Texas 77030, United States
    Recruiting
    • Sunil Sheth, MD · Principal investigator
  • University of Texas Health Science Center-San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
    • Justin Mascitelli, MD · Principal investigator
  • University of Utah
    Salt Lake City, Utah 84132, United States
    Recruiting
    • Ramesh Grandhi, MD · Principal investigator
  • University of Virginia
    Charlottesville, Virginia 22903, United States
    Recruiting
    • Andrew Carlson, MD · Principal investigator
  • University of Washington
    Seattle, Washington 98104, United States
    Recruiting
    • Michael Levitt, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Feb 2029, 51 months after the start.

Of 44 interventional studies with no phase under Hematoma, Subdural, Chronic, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 51 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Apr 4, 2024
StartActual
Nov 1, 2024
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2029
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06347796
Responsible party
Sponsor
First posted
Apr 4, 2024
Start date
Nov 1, 2024
Primary completion
Feb 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
May 22, 2026

Study contacts

Jessica Spahn
Contact
jlspahn@utmb.edu
409-266-8859
Roberto Garcia
Contact
robgarci@utmb.edu
409-772-3182

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion